Introduction
Airways diseases, especially chronic obstructive pulmonary disease (COPD) and asthma, are a major international health concern; COPD is the now the third leading cause of death in the U.S. Most cases are linked to cigarette smoking, although other environmental exposures can also cause disease. One predominant clinical phenotype is chronic bronchitis [1] [2] [3] . Chronic bronchitis is particularly troubling as it can often dominate symptoms, is associated with pulmonary exacerbations, and presently has few treatment options. Chronic bronchitis, asthma, and non-CF bronchiectasis (NCFBE) share many clinical and pathologic features with cystic fibrosis (CF), a model obstructive lung disease caused by gene mutations in the cystic fibrosis transmembrane conductance regulator (CFTR). This overlap motivates investigators to explore CFTR dysfunction as a central disease mechanism and provides a possible joint therapeutic target. The discovery of CFTR potentiators, including the recently FDA-approved agent ivacaftor that can also potentiate even wild-type forms of CFTR, may therefore represent a new therapeutic strategy. Here we review the potential element of acquired CFTR dysfunction, with an emphasis on COPD, and the possibility of CFTR-specific treatment in other airway diseases.
Acquired CFTR dysfunction in smoking-related diseases
There is a longstanding interest in the effects of cigarette smoking on epithelial ion transport. The prior literature of CFTR dysfunction in response to cigarette-smoke exposure was previously reviewed [4 ].
More recently, multiple prospective studies have established that acquired smoking-induced CFTR dysfunction affects the health of COPD smokers and correlates with disease severity and clinical symptoms. Cigarette smokers and COPD patients exhibited reduced CFTR function by nasal potential difference (NPD) measurements, and these differences were accompanied by reduced CFTR mRNA levels from the nares [5,6 ,7 ] . This was also confirmed in the lower airways [7 ] . In these studies, CFTR dysfunction was tightly associated with symptoms of chronic bronchitis [5, 7 ] , and was positively correlated with reduced forced expiratory volume in one second (FEV 1 ) in the lungs of patients with COPD [8].
While reduced CFTR activity in the airways was supported by previous studies in the epithelial cells, deficient CFTR function was also found to be present systemically in the sweat glands and gastrointestinal tract, indicating that systemic therapy for CFTR may be most appropriate [9] . Each of these studies excluded patients that harbor one or more genetic mutations in CFTR, indicating inheritance was not a factor in these diseases. Sweat rate studies demonstrated that CFTR-dependent sweat secretion increases when smokers quit smoking for 2 weeks, indicating CFTR function is compromised upon smoking but has the potential to recover [10].
Current evidence implicates acrolein and cadmium as cigarette-smoke constituents that block CFTR function in vitro and can also reach detectable levels in humans [11, 12 ]. These toxic ingredients are also present in other forms of indoor and outdoor air pollution, and can themselves activate redox pathways [13] that have also been implicated in acquired CFTR dysfunction [14] . In addition, unpublished data indicates that electronic cigarettes may cause acquire CFTR dysfunction in vitro. These agents may be potentially amenable to therapeutic intervention. Certainly, the chronic use of electronic cigarettes is now considered a concern in lung disease [15] .
The mechanistic basis of acquired CFTR dysfunction at a molecular level includes reduced CFTR mRNA expression, diminished protein stability, and reduced channel gating. In vitro and in vivo studies have shown that cigarette smoke affects CFTR mRNA levels [5, 16 ]. Since smoking also increases mucus expression and reduces cilia beat frequency and impairs ciliagenesis [17] , even small decrements in CFTR function are likely to impose marked effects on airway physiology and mucus clearance. Given the variety of pathophysiological mechanisms for CFTR dysfunction, numerous therapeutic interventions may be possible. These pathways are summarized in Figure 1 .
CFTR dysfunction in non-smoking related COPD deleterious effects of cigarette smoking, redox-induced injury might be involved [7 ] , and neutrophil elastase itself may degrade CFTR channels [18 ] . Understanding the differences among these COPD populations warrants further study to assess their relationship to CFTR.
Acquired CFTR dysfunction in asthma and non-CF bronchiectasis (NCFBE)
Asthma is an episodic airways disease characterized by recruitment of various inflammatory cells to the airways which are exploited to treat some phenotypes of asthma [19] . Persistence of this inflammatory process drives epithelial surface and glandular mucus metaplasia that characterizes the airway remodeling present in asthmatics. The resultant mucus is pathologically distinct from normal subjects, particularly during status asthmaticus [20] . The abnormal mucus in asthmatics shares properties of CF mucus including increased mucin density, high plasma protein concentrations, and distinctly high protease levels (e.g. neutrophil elastase) [20, 21] . Notably, many of these features are present in patients with clinically severe asthma at the onset of neutrophilassociated inflammation [22] .
In asthma, airway metaplasia and pathological alteration of mucus are associated with airway plugging [23] due to impaired mucus clearance. These processes cause episodic mucus plugging during acute exacerbations that complicate severe asthma [23] . In its most severe and chronic form, asthma that is affected by bronchiectasis has particularly poor outcomes that include increased infectious burden, exacerbation frequency, and poor treatment response, which is reminiscent of a mild form of CF [24] .
While there is a large body of literature that has examined the link between genetic abnormalities in the CFTR gene and the propensity for asthma [25] , it is unclear if the general asthma patient population has CFTR dysfunction [26, 27] . However, more recent evidence has suggested a link between neutrophilic bronchitis-type asthma and Phe508del-heterozygosity [25, 28] , suggesting a need to further phenotype patients for CFTR defects.
Other studies have examined whether asthmatic inflammation may induce altered CFTR function in the absence of genetic mutations. While IL-13 may reduce CFTR in isolated cell models [29] , chronic IL-4 and IL-13 exposure enhances CFTR activity in mature human airway monolayers [30, 31] . This was confirmed in in vivo mice tracheal studies and in a mouse fungalexposure model [32] . Thus, typical allergic pathways positively affect CFTR dysfunction [33] . However, new evidence links non-allergic asthma with CFTR dysfunction in human nares [34] , but the mechanism is unknown. Thus, whether non-allergic (possibly neutrophilic) or exacerbating asthma are conditions of CFTR dysfunction remains open to future investigation.
Non-CF bronchiectasis (NCFBE) is a disorder characterized by neutrophilic inflammation and cyclical infection and mucus obstruction, much like CF and chronic bronchitis [35, 36] . There is evidence that bronchiectasis may represent a spectrum of CFTR-related disorders as there are increased frequencies of CFTR mutations in patients in various studies [37] . In addition to the association of CFTR mutant alleles with bronchiectasis, CFTR functional defects have been discovered in patients harboring no-CFTR mutant alleles using sweat chloride and nasal potential difference measurements [38] . Thus, while the mechanisms of CFTR dysfunction in asthma and NCFBE are not as well understood, there is evidence that certain subsets of patients demonstrate CFTR dysfunction. The association of CFTR dysfunction with complications of these diseases, however, is unknown.
Therapy challenges in COPD
Although COPD is among the most common causes of death worldwide, no current pharmacologic treatments alter its natural history [39, 40] . Therapies including bronchodilators and inhaled corticosteroids do not reduce mortality in COPD [41] [42] [43] . Additionally, inhaled steroids in COPD are associated with an increased risk of pneumonia and do not alter mucus obstruction or its clearance [41, 44, 45] . Mucolytic therapy for COPD has yielded marginal benefits thus far [46] [47] [48] . Owing to the lack of efficacy of currently available agents, poor bioavailability, and failure to deliver the drug to the distal airways to affect mucus obstruction, an improved approach that targets the small airways (with a potent and orally available agent) could be expected to overcome these limitations. This type of therapy would be expected to improve mucus stasis, an important cause of residual airway obstruction in COPD not addressed by current therapies. Furthermore, these types of therapies are necessary even after tobacco cessation because COPD patients have continued lung function decline and increased mortality after tobacco cessation [49] .
CF therapies in non-CF lung diseases
Since there is shared pathophysiology between CF and other airway diseases, several trials have looked at previously approved CF therapies for other lung diseases. Although not all efforts have been successful, including randomized trials for dornase alfa in COPD and non-CF bronchiectasis [34] , there are shared benefits of intravenous corticosteroids during exacerbations [50] , chest physiotherapy [51] , and, most recently, the chronic administration of azithromycin to reduce acute exacerbations [52, 53] . This experience suggests that some agents effective in CF may also be efficacious in COPD and other airways diseases.
CFTR modulator therapy in CF
'CFTR potentiators' are a class of agents developed to correct the underlying gating defects of mutant CFTR that is transported to the cell surface [54, 55] . The archetype agent ivacaftor (formerly VX-770) potentiates multiple CFTR forms, including WT, G551D (a class III mutation), and other mutations with residual expression or function (Class III, IV, and V) in primary airway epithelial monolayers, but only if there is a sufficient cell surface number of channels [56 ] . Ivacaftor is now FDA approved for treatment of CF with 33 different CFTR mutations. CF patients treated with ivacaftor demonstrate improved CFTR function, mucociliary clearance (MCC), pulmonary function, and exacerbation frequency [57 ] .
While CFTR potentiators were originally developed to restore activity to mutant CFTR, some CFTR potentiators increase wild-type CFTR activity [5, 58 ] . For example, both ivacaftor and other CFTR potentiators activate wild-type CFTR by augmenting open channel probability [59 ,60,61] . Because CFTR regulates airway surface liquid (ASL) depth [62] which in turn determines mucociliary clearance (MCC) [63] [64] [65] , potentiation of CFTR anion secretion may result in augmented mucus transport compared to resting conditions [66] . A recent study examined the role of ivacaftor in primary human bronchial epithelial (HBE) cells and human bronchi that were exposed to cigarette smoke extract [66] . Although it was known that cigarette smoking was linked to acquired CFTR dysfunction, its impact on mucociliary transport was less characterized. In this study, Raju et al. demonstrated that cigarette smoke extract (CSE) reduced CFTR-dependent currents within minutes, decreased airway surface liquid depth and reduced ciliary beat frequency within 60 min of exposure [56 ] . Chronic exposure also decreased CFTR protein levels, but more importantly, the channel gating and open probability were decreased $75% rapidly following CSE exposure (Figure 2 ) [56 ] . Of note, the effects of CSE were reversed by coadministration with ivacaftor, illustrating the importance of this potentiator in mucociliary clearance.
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Figure 2
Cigarette smoke extract acutely reduces CFTR-dependent channel opening. A. Representative recording from macropatch of HEK293 cells expressing wildtype CFTR then exposed to low dose PKA inhibitor (PKI, 40 U/ml) to ascertain phosphorylation status then CSE (1%). CFTR Inh -172 (10 mM) was added to confirm CFTR dependence. Holding potential was À50 mV. 
CFTR modulators in the treatment of chronic bronchitis
Recent in vitro work demonstrating that ivacaftor can reduce CFTR dysfunction and restore ASL and mucus transport in smoke-exposed human tissue [5, 12 ] has set the stage for larger trials of ivacaftor in COPD with chronic bronchitis. As ivacaftor actively augments channel gating, which is affected in COPD due to smoking [12 ] , to restore ASL depth and mucociliary transport acutely [56 ] , this represents a logical approach to addressing the pathway.
In a recent study, 12 active or former smokers with COPD and chronic bronchitis were enrolled in a pilot evaluation of ivacaftor treatment [67 ] . Ivacaftor-treated patients had non-significant improvements in CFTR function compared with those receiving placebo, as detected by improved sweat chloride concentrations and nasal potential differences. Ivacaftor patients also had non-significant improvements in symptoms as detected by changes in the Breathlessness, Cough and Sputum Scale (BCSS) that exceeded the minimally clinical important difference of 1 unit. The patients with the largest improvement in sweat chloride also had the greatest improvement in BCSS and the highest sweat chloride concentration at baseline, indicating more severe CFTR dysfunction that was partially reversible. Pharmacokinetic analysis revealed stable ivacaftor concentrations, with an area under the curve that mirrored the experiences of patients with cystic fibrosis. Although this pilot trial was underpowered and potentially too brief to detect definitive changes in lung function, there were improvements in CFTR activity and respiratory symptoms. These results set the stage for longer trials to identify the effects of CFTR potentiation on clinical outcomes in patients with chronic bronchitis with a substantial degree of acquired CFTR dysfunction at baseline. These trials also emphasize the importance of delineating the most appropriate patient phenotypes for future studies that involve differentiation based on baseline CFTR functional status (and/or CFTR genotype), severity of lung disease, smoking status, and level of concomitant emphysema and bronchiectasis [4 ,68] .
In addition to rescuing mutant CFTR, we speculate that next generation potentiators (in development by Novartis and Galapagos Pharmaceuticals) may target the CFTR gating defect in smoke-exposed human tissue. In addition, CFTR correctors, which restore and/or enhance cell surface-localized numbers of channels may be explored in future research.
PDE-4 inhibition to treat CFTR dysfunction
In addition to direct stimulation of CFTR activity with potentiators, new therapies may offer promise for alternative means to activate wild-type CFTR. Roflumilast is a phosphodiesterase-4 (PDE-4) inhibitor approved for the treatment of frequent exacerbations in COPD patients with chronic bronchitis [69] . Though originally intended to treat inflammation in COPD across the disease spectrum, it was only shown to be effective in patients with chronic bronchitis [70] . Roflumilast activates CFTR by augmenting its phosphorylation in a manner that is competitive with cAMP-dependent stimuli, a distinction from CFTR potentiators [71] . Roflumilast also restored CFTR function in human bronchial epithelial cells exposed to cigarette smoke [72] . Downstream of CFTR augmentation, roflumilast augmented ASL depth, including cells affected by cigarette smoking [71, 72] . The effect of roflumilast on CFTR expression has not been reported.
The activity of roflumilast on CFTR may partially explain its therapeutic benefit in COPD patients with chronic bronchitis and frequent exacerbations since this phenotype is associated with an increased prevalence of CFTR dysfunction [7 ,12 ] ; this also adds additional credence to the hypothesis that CFTR potentiation may be beneficial in COPD. CFTR activation and fluid secretion in the intestine was also shown to occur with roflumilast, perhaps explaining the adverse event of diarrhea observed after administration [71] . One implication of this is that COPD patients also commonly use betaadrenergic agonists, which increase intracellular cAMP; whether CFTR activators that operate by this general mechanism, such as roflumilast, are disadvantaged as compared to other cAMP-independent CFTR modulators, such as CFTR potentiators, warrants further study.
Conclusions
Many airway diseases demonstrate mucus obstruction as a common pathophysiological mechanism. Data in COPD, especially the chronic bronchitis phenotype, indicate that this mechanism may be due to decreased CFTR function in addition to other causes of compromised mucus transport. The promise of CFTR modulators brings interest in the treatment of acquired CFTR dysfunction in COPD. Recently, the CFTR potentiator ivacaftor was tested for safety and early efficacy with positive outcomes in COPD patients with chronic bronchitis [67 ] . Given the increasing evidence for CFTR dysfunction in asthma and COPD, there is reason to consider expanding the investigation of CFTR modulators to these disorders.
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